Type | Subsidiary |
Parent Company | Biogen |
HQ | Newton, MA, US |
Founded | 2008 |
Website | karyopharm.com |
Cybersecurity rating | BMore |
Founding Date | 2008 |
Total Funding | $248.7 m |
Investors | New Leaf Venture Partners, Delphi Ventures, Foresite Capital |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 171.0k | 21.0k | 21.0k | 150.0k | 75.0k | 59.0k | 48.0k | 68.0k | 19.9m | 239.0k | 155.0k | 9.5m | 13.1m | 18.1m | 33.5m | 21.3m | ||||||
Cost of goods sold | 1.0m | |||||||||||||||||||||
Gross profit | 12.1m | |||||||||||||||||||||
Gross profit Margin, % | 92% |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 52.9m | 144.9m | 132.3m | 227.1m | 51.5m | 24.2m | 43.5m | 42.2m | 37.7m | 43.9m | 25.6m | 55.4m | 54.5m | 37.5m | 119.0m | 101.6m | 83.5m | 75.5m | 168.0m | 202.2m | 103.1m | 82.3m |
Accounts Receivable | 7.9m | 9.3m | 9.6m | |||||||||||||||||||
Prepaid Expenses | 658.0k | 2.7m | 3.0m | 4.2m | 2.9m | 4.1m | 3.1m | 1.7m | 1.5m | 3.4m | 2.1m | 2.1m | 2.1m | 2.4m | 3.4m | 4.8m | 7.0m | 5.7m | 5.3m | 7.6m | 8.0m | 8.2m |
Inventories | 100.0k | 970.0k | 1.7m | 2.0m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.8m) | (13.7m) | (30.1m) | (49.8m) | (26.1m) | (58.8m) | (89.1m) | (27.1m) | (57.2m) | (82.6m) | (29.9m) | (59.3m) | (89.9m) | (38.5m) | (72.1m) | (120.2m) | (66.2m) | (109.6m) | (150.9m) | (52.9m) | (99.4m) | (152.9m) |
Depreciation and Amortization | 106.0k | 43.0k | 85.0k | 191.0k | 136.0k | 292.0k | 457.0k | 179.0k | 358.0k | 537.0k | 183.0k | 363.0k | 539.0k | 169.0k | 353.0k | 541.0k | 245.0k | 487.0k | 730.0k | 242.0k | 480.0k | 715.0k |
Inventories | (100.0k) | (624.0k) | (1.3m) | (1.7m) | ||||||||||||||||||
Accounts Payable | 673.0k | 1.5m | 1.7m | 362.0k | 268.0k | (1.8m) | (2.1m) | 294.0k | 233.0k | (1.7m) | (522.0k) | (1.5m) | (2.9m) | (773.0k) | (1.9m) | (3.4m) | (2.0m) | (3.2m) | (1.2m) | 711.0k | 903.0k | 1.4m |
USD | Q3, 2013 |
---|---|
Financial Leverage | -1.2 x |
When was Karyopharm Therapeutics founded?
Karyopharm Therapeutics was founded in 2008.
Who are Karyopharm Therapeutics key executives?
Karyopharm Therapeutics's key executives are Sharon Shacham, Garen Bohlin and Brian Austad.
How many employees does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 437 employees.
What is Karyopharm Therapeutics revenue?
Latest Karyopharm Therapeutics annual revenue is $40.9 m.
What is Karyopharm Therapeutics revenue per employee?
Latest Karyopharm Therapeutics revenue per employee is $93.6 k.
Who are Karyopharm Therapeutics competitors?
Competitors of Karyopharm Therapeutics include CytomX Therapeutics, Calithera Biosciences and AVEO Pharmaceuticals.
Where is Karyopharm Therapeutics headquarters?
Karyopharm Therapeutics headquarters is located at 85 Wells Ave, Newton.
Where are Karyopharm Therapeutics offices?
Karyopharm Therapeutics has offices in Newton, München and Tel Aviv-Yafo.
How many offices does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 3 offices.
Receive alerts for 300+ data fields across thousands of companies